The JAK inhibitor (JAKi) ruxolitinib is standard treatment for intermediate- or high-risk myelofibrosis (MF), but fewer than 50% of patients achieve spleen response (≥ 35% reduction in spleen volume) or significant improvement in symptom burden \[[@CR1], [@CR2]\].

The Hedgehog signaling pathway is involved in primitive and definitive bone marrow hematopoiesis and maintenance of hematopoietic precursors \[[@CR3]\]. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib may improve response \[[@CR4], [@CR6]\]. The HPI vismodegib is approved for the treatment of advanced basal cell carcinoma \[[@CR5]\].

We present findings from MYLIE, an open-label, multi-center, phase Ib study (ClinicalTrials.gov, NCT02593760) of vismodegib plus ruxolitinib in patients with intermediate- or high-risk MF.

Eligible patients were adults with pathologically confirmed primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF who were considered intermediate-1, intermediate-2, or high risk, with a peripheral blood blast count \< 10% and palpable splenomegaly \> 5 cm below the left costal margin, and who had no prior treatment with a JAKi or an HPI.

Patients received vismodegib (150 mg/day orally) and ruxolitinib (starting dose 15 or 20 mg orally twice daily, depending on baseline platelet count) for up to 48 weeks, or until disease progression, unacceptable toxicity, or consent withdrawal.

Efficacy end points were assessed at 24 and 48 weeks after the first dose of study medication and included spleen response rate (≥ 35% reduction in spleen volume), disease response rate (complete remission \[CR\] and partial remission \[PR\]), clinical improvement (anemia, spleen, or symptom response without disease progression or increase in severity of anemia, thrombocytopenia, or neutropenia), anemia response rate, and improvement in bone marrow fibrosis of ≥ 1 grade (Additional file [1](#MOESM1){ref-type="media"}). Pharmacokinetics of total and unbound vismodegib were characterized using pre-dose samples obtained at weeks 6, 12, 24, 36, and 48 and were compared with data from patients with advanced basal cell carcinoma \[[@CR7]--[@CR9]\].

Ten patients were enrolled at four sites in the USA (2), Canada (1), and Italy (1) (Table [1](#Tab1){ref-type="table"}). Patients received vismodegib plus ruxolitinib for a median of 330.0 days. Eight patients completed 48 weeks of treatment; one patient discontinued owing to lack of efficacy at 35 weeks and one because of a vismodegib-related adverse event (AE; dysgeusia) at 23 weeks.Table 1Baseline characteristics*N* = 10Age, median (range), years67.5 (46--82)Sex, *n* Male7 Female3ECOG performance status, *n* 04 16Myelofibrosis type, *n* Primary MF6 Post-ET3 Post-PV1DIPSS risk status, *n* High1 Intermediate-26 Intermediate-13Transfusion-dependent at study entry Yes3 No7*DIPSS* International Working Group-Myeloproliferative Neoplasms Research and Treatment Dynamic International Prognostic Scoring System, *ECOG* Eastern Cooperative Oncology Group performance status, *PV* polycythemia vera

At week 24, spleen response was observed in one and three patients by investigator and central review, respectively (Fig. [1a](#Fig1){ref-type="fig"}). At week 48, of eight patients, two and four patients had spleen response by investigator and central review, respectively.Fig. 1Spleen volume change from baseline per central and investigator review (**a**) and symptom response change (**b**) at week 24, by patient. Threshold for clinical efficacy at 35% reduction in spleen volume and 50% reduction in the MPN-SAF TSS is indicated by the dotted line. Spleen volume was assessed by CT or MRI, both by a local radiologist and a central independent review committee. Symptom score data were not available for three patients, including the patient who discontinued early. *CT* computed tomography; *MPN-SAF TSS* Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score; *MRI* magnetic resonance imaging

Of seven evaluable patients, five had symptom response at week 24 (Fig. [1b](#Fig1){ref-type="fig"}). At week 48, symptom response was achieved in two patients with no previous symptom response, three patients maintained symptom response from week 24, and two were not evaluable. No patients experienced anemia response. Of nine patients evaluable for disease response at week 24, one experienced PR, one experienced clinical improvement, and seven had stable disease. Of eight patients on study at week 48, one maintained clinical improvement, six had stable disease, and the patient with PR had relapsed.

From baseline, no patients experienced a ≥ 1-grade improvement in fibrosis at week 24 per central review (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Of five patients with bone marrow biopsy specimens at week 48, a 1-grade improvement in fibrosis was observed in one and two patients by central review and local pathology review, respectively.

All ten patients experienced at least one AE (Additional file [1](#MOESM1){ref-type="media"}: Table S2): five patients (50%) experienced grade ≥ 3 AEs, and three patients (30%) experienced a total of six serious AEs (grade 4 anemia, grade 3 pneumonia, grade 4 sepsis, grade 3 vomiting, grade 3 lung infiltration, grade 3 infectious enterocolitis). No patients died during the study period. Dose interruptions or modifications are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S3.

Total and unbound steady-state vismodegib plasma concentrations in patients with MF were consistent with those obtained in patients with basal cell carcinoma (Additional file [1](#MOESM1){ref-type="media"}: Table S4) \[[@CR7], [@CR8]\].

Vismodegib combined with ruxolitinib did not result in greater efficacy than ruxolitinib alone \[[@CR1]\], consistent with other trials of HPIs in MF \[[@CR6], [@CR10]\]. The combination was tolerable, and no new safety signals were seen. However, because of lack of evidence of a disease-modifying effect after addition of vismodegib to ruxolitinib, further evaluation of this combination will not be pursued.
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